comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 23:20:19 - browse：1488

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： ASCO eve: Let’s set the table for this year's meeting

knowledge

Wikipedia

WSS

David Liu startup to focus on CRISPR delivery

David Liu startup to focus on CRISPR delivery

UnitedHealth argues against case alleging wrongful AI care denials

What happened to the House vote on health price transparency?

Midwives could help bridge maternal health disparities in the U.S.

Chamber of Commerce, DOJ clash in court over drug prices

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

New air purifier tech could be key to improving indoor air quality

Questions and answers about ramping up H5N1 bird flu vaccine

Cancer drug shortages should be causing more outrage

PBMs drew scrutiny in House hearing — and so did pharma

DIEP, the 'gold standard' of breast reconstruction, is under threat

Eli Lilly CEO gives to Mike Pence presidential super PAC

Guidelines to prevent youth baseball injuries need more muscle

ASCO eve: Let’s set the table for this year's meeting

Malaria cases in Florida and Texas: Here’s what you need to know

The struggle to figure out which patients 'deserve' Wegovy

explore

Investigation reveals sickle cell patients pressured into sterilizations

House panel takes first step toward fixing drug shortages

Study finds gene variants tied to breast cancer risk in Black women

Medicare to pay more for cardiac rehab in hospital outpatient clinics

The struggle to figure out which patients 'deserve' Wegovy

Free Covid tests will again be offered to all U.S. households

knowledge

Wikipedia

focus

Wikipedia